Protein markers for estrogen receptor (er)-positive luminal a (la)-like and luminal b1 (lb1)-like breast cancer

The method of any of the preceding claims, wherein the breast cancer marker comprises at least two or more markers, wherein each of the two of more markers are selected from one or any combination of the proteins set forth in Tables 1 and 2.

The method of any of the preceding claims, wherein the level of the breast cancer marker is detected by one or more of HPLC/UV-Vis spectroscopy, enzymatic analysis, mass spectrometry, NMR, immunoassay, ELISA, chromatography, or any combination thereof, or by determining the level of its corresponding mRNA in the biological sample.

The method of any of the preceding claims, further comprising selecting a treatment regimen based on the molecular subtype of breast cancer in the subject.

A method for identifying an agent that modulates luminal A (LA)-like breast cancer, comprising:

• (a) contacting a cell with a test compound,
• (b) determining the expression and/or activity of a breast cancer marker in the cell, wherein the breast cancer marker comprises one or more markers selected from Tables 1 and 2, and
• (c) identifying an agent that modulates the expression and/or activity of the breast cancer marker in the cell as an agent that modulates LA-like breast cancer.

A method for identifying an agent that modulates luminal B1 (LB1)-like breast cancer, comprising:

• (a) contacting a cell with a test compound,
• (b) determining the expression and/or activity of a breast cancer marker in the cell, wherein the breast cancer marker comprises one or more markers selected from Tables 1 and 2, and
• (c) identifying an agent that modulates the expression and/or activity of the breast cancer marker in the cell as an agent that modulates LB1-like breast cancer.

A method of treating luminal A (LA)-like breast cancer in a subject, comprising administering to the subject a modulator of a breast cancer marker, wherein the breast cancer marker comprises one or more markers selected from Tables 1 and 2.

A method of treating luminal B1 (LB1)-like breast cancer in a subject, comprising administering to the subject a modulator of a breast cancer marker, wherein the breast cancer marker comprises one or more markers selected from Tables 1 and 2.

A kit for detecting a molecular subtype of luminal A (LA)-like breast cancer in a biological sample from a subject having breast cancer, comprising one or more reagents for measuring the level of a breast cancer marker in the biological sample from the subject, wherein the breast cancer marker comprises one or more markers selected from Tables 1 and 2 and a set of instructions for measuring the level of the breast cancer marker.

A kit for detecting a molecular subtype of luminal B1 (LB1)-like breast cancer in a biological sample from a subject having breast cancer, comprising one or more reagents for measuring the level of a breast cancer marker in the biological sample from the subject, wherein the breast cancer marker comprises one or more markers selected from Tables 1 and 2 and a set of instructions for measuring the level of the breast cancer marker.

A panel for use in a method for determining the molecular subtype of breast cancer in a subject, the panel comprising one or more detection reagents, wherein each detection reagent is specific for the detection of a breast cancer marker, wherein the breast cancer marker comprises one or more markers selected from Tables 1 and 2.